UNSPSC 51384534: Dexibuprofen

This classification denotes an ibuprofen analog and nonsteroidal anti-inflammatory agent with the molecular formula C13H18O2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 671DKG7P5S, chemically known as benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)-, (s)- but more generally known as dexibuprofen, which bears U.S. National Institutes of Health Compound Identifier 39912. European Medicines Agency schedules Dexibuprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07030MIG.

World Health Organization schedules dexibuprofen in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. DEXIBUPROFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51384534 Dexibuprofen, a Commodity code, nominally names a single anti-inflammatory pharmaceutical product, but recent state and local procurement activity under the code shows minimal direct solicitation for dexibuprofen itself. Instead, the code appears to tag broader pharmaceutical and over-the-counter procurement initiatives, including naloxone acquisition, generic multi-source pharmaceutical supply agreements, and direct-to-manufacturer prescription programs. The work being solicited centers on the supply, warehousing, and delivery of pharmaceutical products to state and local health agencies, community health departments, and cooperative purchasing alliances that serve multiple jurisdictions. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances administering on behalf of participating state and local facilities (Minnesota Multistate Cooperative Purchasing Alliance).

Recent activity spans Florida, Texas, Minnesota, and Oregon, with the Minnesota MMCAP alliance representing the broadest geographic reach across participating state and local government entities. Three representative recent solicitations illustrate the current scope: Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: the due date appears misaligned with the posting date); Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs without a binding deadline; and Minnesota Department of Administration's MMCAP issued RFP S1070000015802 in January 2026 seeking manufacturers of generic multi-source pharmaceuticals and OTC products across authorized wholesalers, with proposals due March 26, 2026. Vendors must meet FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act requirements, and maintain substantial insurance coverage. The MMCAP RFP weights price competitiveness at 75 percent and requires vendors to sustain relationships with at least two of three authorized wholesalers.